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Strengths and limitations of this study
 Ź This is the only systematic review and meta- analysis 
assessing the role of long- acting somatostatin ana-
logues in both autosomal polycystic kidney disease 
and polycystic liver disease to date.
 Ź Only randomised control and randomised cross- over 
trials were included.
 Ź Variation in baseline total kidney volume in multiple 
trials may confound results.
 Ź There are a small number of trials available, largely 
with small patient numbers.
 Ź There was no consensus on somatostatin analogue 
formulation with variation between studies.
ABSTRACT
Objectives A number of randomised control trials (RCTs) 
investigating the effects of long- acting somatostatin 
analogues in autosomal dominant polycystic kidney 
disease (ADPKD) and polycystic liver disease (PLD) have 
been recently reported. We sought to evaluate all available 
RCTs investigating the eficacy of somatostatin analogues 
treatment in ADPKD and PLD.
Data sources Electronic databases; Pubmed,  
Clincaltrials. gov and Cochrane Central Register of 
Controlled Trials
Eligibility criteria for selecting studies RCTs and 
randomised cross- over trials comparing the effects of 
somatostatin analogue treatment with controls in patients 
with ADPKD or PLD.
Data extraction and synthesis Data extraction and 
bias assessments were performed by two independent 
reviewers between January and May 2019. Outcomes 
assessed included estimated glomerular iltration rate 
(eGFR), total kidney volume (TKV), total liver volume (TLV), 
progression to end stage renal failure (ESRF) and adverse 
effects. Data were pooled using a random- effects model 
and reported as relative risk or mean difference with 95% 
CIs.
Results Meta- analysis was performed of six RCTs 
or randomised cross- over trials and three secondary 
analyses. A total of 592 patients were included. Compared 
with controls, somatostatin analogue treatment 
signiicantly reduced TLV (mean difference −0.15 L, 
95% CI −0.26 to −0.03, p=0.01). There was no signiicant 
effect on TKV (mean difference −0.19 L, 95% CI −0.50 
to 0.12, p=0.23) or eGFR (mean difference 0.27 mL/
min/1.73 m
2, 95% CI −2.03 to 2.57, p=0.82). There was 
no effect on progression to ESRF. Somatostatin analogues 
were associated with known adverse effects such as 
gastrointestinal symptoms.
Conclusions The available RCT data show improvement 
in TLV with somatostatin analogue treatment. There was 
no beneit to TKV or eGFR in patients with ADPKD, while 
being associated with various side effects. Further studies 
are needed to assess potential beneit in reducing cyst 
burden in patients with PLD.
INTRODUCTION
Autosomal dominant polycystic kidney 
disease (ADPKD) is the most prevalent 
monogenic disease in the world, the single 
most common inherited kidney disease and 
the fourth most common cause of end stage 
renal failure (ESRF).1 Prevalence rates for 
ADPKD vary greatly in different populations 
and countries, with rates reported between 
1:400 and 1:10002 although more recent esti-
mates suggest a point prevalence of clinically 
diagnosed cases of 4:10 000 in Europe.3
The cardinal feature of ADPKD is the 
development of large numbers of fluid- filled 
cysts that disrupt normal kidney structure, 
leading to the gradual loss of renal function. 
The disease is usually progressive and results 
in the need for dialysis or renal transplan-
tation. ADPKD accounts for approximately 
5%–10% of all patients with ESRF at an esti-
mated cost of 1.6 billion euro per year across 
Europe.3 Alongside renal morbidity, ADPKD 
is associated with several common extrarenal 
manifestations including polycystic liver 
disease (PLD) and intracranial aneurysms 
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which may further worsen individual patient’s disease 
burden.4
ADPKD most commonly results from a germline muta-
tion in either PKD1 or PKD2 while a number of patients 
with ADPKD who are negative for either gene carry 
GANAB (glucosidase II alpha subunit) mutations.5 PKD1 
mutations are present in approximately 80% of ADPKD 
patients and are associated with an earlier onset of ESRF 
compared with PKD2 mutations.6 The growth and expan-
sion of cysts leads to the destruction of normal kidney 
structure and results eventually in the permanent loss 
of function and ESRF.3 PLD is the most common extra-
renal manifestation of ADPKD and has been reported to 
occur in approximately 83% of patients. More rarely, PLD 
can occur in isolation from ADPKD, due to mutations in 
other genes such as protein kinase C substrate 80 K- H 
(PRKCSH), SEC63, SEC61B, alpha-1,3- glucosyltransferase 
(ALG8) and low- density lipoprotein receptor- related 
protein 5 (LRP5), leading to autosomal dominant 
polycystic liver disease (ADPLD).7–10 There is however 
increasing recognition of a phenotypic overlap between 
patients with ADPKD and ADPLD with a spectrum of 
disease severity.11 12
At present, there is no cure for ADPKD, and only one 
drug, tolvaptan, has been approved to slow renal disease 
progression.13 However, tolvaptan has been associated 
with a variety of poorly tolerated adverse effects espe-
cially profound aquaresis and rare cases of hepatotoxicity 
making it unsuitable or intolerable in many patients.14 
Therefore there is a significant need for alternate or 
adjunctive treatments in the management of ADPKD and 
PLD.
Cyst growth in ADPKD and PLD has been linked to 
the activation of several different signalling pathways, 
particularly several involving cyclic adenosine mono-
phosphate (cAMP). Increased levels of cAMP have been 
associated with accelerated cyst development, cell prolif-
eration and disease progression; thus reducing cAMP 
levels represents a logical therapeutic aim.15 Targeting 
somatostatin receptors with long- acting somatostatin 
analogues such as octreotide has been shown to reduce 
cAMP accumulation and disease progression in experi-
mental models of ADPKD and PLD.16 Consequently, the 
use of somatostatin analogues has been proposed as a 
potential treatment for ADPKD and ADPLD, with several 
trials having been recently completed. While there have 
been two previous individualised meta- analysis’ assessing 
somatostatin analogues in PLD,17 18 no focused systematic 
review of all trials in ADPKD and PLD has been published 
to date.
METHODS
Search strategy
The search strategy used consisted of electronic database 
searches using key terms such as ADPKD, somatostatin 
and PLD. Three online databases were used: Pubmed 
(with a search filter for clinical trials),  Clincaltrials. gov 
and Cochrane Central Register of Controlled Trials. A 
summary of search terms used and the strategy is shown 
in online supplementary table 1. Searching began in 
January 2019 and was completed on 10 May 2019.
Study selection
Inclusion criteria were as follows:
1. Randomised control trial (RCT) with appropriate con-
trol subjects.
2. Intervention with an appropriate long- acting soma-
tostatin analogue administered monthly at any dose in 
any formulation.
3. Relevant outcomes to this review (total kidney volume 
(TKV), total liver volume (TLV), estimated glomerular 
filtration rate (eGFR), blood pressure (BP), adverse 
effects, progression to ESRF, mortality and hospital ad-
missions).
4. Patients with a clinical and radiological diagnosis of 
ADPKD or PLD.
Only adults were included. There were no restric-
tions on baseline renal function or genetic analysis. 
Secondary analysis of previous trials was accepted if the 
trial in question was also included in this review. Only 
trials available in English were included. Studies with 
interventions that included another treatment (such as 
combination with tolvaptan), observational trials and 
pooled analysis studies were excluded. Patients with 
liver or kidney transplants were excluded from TKV 
and eGFR or TLV analysis, respectively. Patients with 
Chronic Kidney Disease Stage 5 (CKD5) or receiving 
dialysis were also excluded.
Primary outcomes
 Ź TKV in ADPKD.
 Ź TLV in PLD.
 Ź eGFR decline in ADPKD.
Secondary outcomes
 Ź Adverse effects (blood glucose, abdominal pain, diar-
rhoea, cholelithiasis, cholecystitis and alopecia).
 Ź Discontinuation rates.
 Ź BP.
 Ź Progression to ESRF.
 Ź All- cause mortality
 Ź Hospital admissions.
Quality assessment
Studies were assessed for bias by two independent reviewers 
using a standardised bias assessment form developed 
by Cochrane reviews and available from the Cochrane 
reviews handbook.19 20 The tool assesses publications for 
various forms of bias, including selection, performance, 
detection, attrition and reporting and were scored as 
high, low or unclear risk of bias for each area. Publication 
bias was assessed using Funnel plots and visual inspection 
in accordance with the Cochrane reviews handbook.20 We 
used the PRISMA checklist to confirm that our review was 
PRISMA compliant.
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Figure 1 Study low diagram.
Data extraction
Data extraction was performed by two independent 
reviewers using a data extraction form developed from a 
standard electronic form for the purposes of this review. 
Data extracted included study details, patient population 
details, relevant outcomes and interventions. In publi-
cations where both TLV and TKV were reported, results 
were separated for patients with PLD and ADPKD which 
allowed individual meta- analysis of both measurements. 
Authors were not contacted for missing data.
Statistics
Statistical analysis was performed using Review Manager 
V. 5.321 with inverse variance used for continuous data 
and Mantel- Haenszel for dichotomous data. A random- 
effects model was used throughout. Effect estimates of 
individual and pooled trial data were represented by 
mean difference or risk ratios with appropriate 95% CIs. 
Standardised mean differences were used for contin-
uous outcomes with different methods of quantification 
between studies. If no final post- treatment mean value 
was reported, mean change from baseline was used and 
the results were analysed together as unstandardised 
mean differences as detailed in the Cochrane hand-
book.20 Results were demonstrated via Forest plots. P 
values were two- tailed and a significance value of <0.05 
was used in all statistical tests. Any missing SD that were 
required were imputed using published methods in the 
Cochrane handbook.20 Heterogeneity was assessed using 
Q values and I² test with scores below 25% deemed low, 
25%–50% medium and >50% high heterogeneity.22 Meta- 
regression was not performed due to the small number of 
studies included.
Patient and public involvement
No patients were involved in the completion of this study.
RESULTS
The search strategy identified 29 publications that had 
potential to be included in this review. Of these trials, five 
were interim analyses of ongoing trials or trial protocols 
and four were unpublished trials. Another six trials were 
not RCTs (observational or safety trials), three used unsuit-
able interventions and two reported irrelevant outcomes. 
See figure 1 for an overview of the study selection process.
A total of six studies were included consisting of five 
RCTs23–27 and one randomised crossover trial.28 Of these, 
four included ADPKD patients alone25–28 and the remaining 
two included patients with PLD and ADPKD, but provided 
a subset of data for ADPKD patients when measuring 
renal function and TKV.23 24 A further three publications 
were included as they were secondary analyses of previous 
studies,29–31 all of which were investigating the change in 
TLV for a subset of patients with PLD in a post- hoc analysis. 
Excluding patient numbers from secondary analysis, a total 
of 592 patients were included.
All included studies recruited both male and female 
participants who were over the age of 18 and with a clin-
ical and radiological diagnosis of ADPKD (according to the 
Ravine Criteria in the majority of studies). The most signifi-
cant variation in inclusion criteria between studies was base-
line renal function. These differing criteria and summaries 
for the included trials and publications are outlined in 
table 1.
Bias risk assessment
Bias assessments are summarised in figure 2. Notable bias 
was detected in blinding for several studies. In ALADIN 
2013 (and Pisani et al30), physicians and staff were not 
blinded to patient allocation groups, and DIPAK-1 (and 
van Aerts et al29) was an open- label study: therefore, both 
had a high risk of bias for blinding of participants. All 
studies except Ruggenentti et al28 reported that TKV 
and TLV measurements were performed by blinded 
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Table 1 Summary of included study characteristics with regards to study details, patient population details, intervention, relevant outcomes, interventions and baseline 
characteristics
Study Study design Country
Follow- 
up period 
(months)
Number 
of 
patients 
(males) Renal function criteria
Imaging 
modality Intervention
Baseline 
characteristics 
mean (±SD)
Relevant 
outcomes
Ruggenenti et 
al28
Randomised, 
crossover, placebo- 
controlled trial
Italy 6 14 (9) Serum creatinine <3.0 mg/
dL, but >1.2 mg/dL (males) 
or >1.0
mg/dL (females)
CT Octreotide- 
LAR, 40 mg 
intramuscularly 
every 28 days
eGFR
 Ź (I) 59.5±25.2
 Ź (C) 57.9±22.4
TKV
 Ź (I) 2551±1053
 Ź (C) 2461±959
TKV, eGFR, 
blood pressure, 
blood glucose 
and adverse 
effects
van Keimpema 
et al24
(LOCKCYST)
Randomised, double- 
blind, placebo- 
controlled trial
The 
Netherlands
6 54 (7) No eGFR restrictions, 
Haemodialysis (HD) 
patients excluded
CT Lanreotide- 
LAR, 120 mg 
intramuscularly 
every 28 days
eGFR
 Ź (I) 83±198
 Ź (C) 91±282
TKV
 Ź (I) 1000±1846
 Ź (C) 1115±3727
TKV, TLV and 
adverse effects
Caroli et al31 Secondary analysis of 
Ruggenenti et al28
Italy 6 14 (9) Serum creatinine <3.0 mg/
dL, but >1.2 mg/dL (males) 
or >1.0
mg/dL (females)
CT Octreotide- 
LAR, 40 mg 
intramuscularly 
every 28 days
TLV
 Ź (I) 1595±478
 Ź (C) 1580±487
  TLV
Hogan et al23 Randomised, double- 
blind, placebo- 
controlled trial
USA 12 42 (6) Patients with a serum 
creatinine
concentration >3 mg/
dL or dialysis- dependant 
excluded
CT Octreotide- 
LAR, 40 mg 
intramuscularly 
every 28 days
eGFR
 Ź (I) 70±27
 Ź (C) 71±27
TKV
 Ź (I) 1142.9±826
 Ź (C) 803.0±269
TLV
 Ź (I) 5907.7±2915
 Ź (C) 5373.9±3565
TKV, TLV, adverse 
effects, eGFR, 
blood glucose 
and blood 
pressure
Caroli et al25
(ALADIN)
Randomised, single- 
blind placebo- 
controlled trial
Italy 36 79 (37) eGFR of 40 mL/min per 
1.73 m² or higher
MRI Octreotide- 
LAR, 40 mg 
intramuscularly 
every 28 days
eGFR
 Ź (I) 90±37
 Ź (C) 76.1±40
TKV
 Ź (I) 1556±1035
 Ź (C) 2161±1274
TKV, eGFR, 
adverse effects, 
blood glucose 
and blood 
pressure
Pisani et al30 Secondary analysis of 
ALADIN
Italy 36 27 (10) eGFR of 40 mL/min per 
1.73 m² or higher
MRI Octreotide- 
LAR, 40 mg 
intramuscularly 
every 28 days
TLV
 Ź (I) 1609±501
 Ź (C) 1693±470
TLV
Continued
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Study Study design Country
Follow- 
up period 
(months)
Number 
of 
patients 
(males) Renal function criteria
Imaging 
modality Intervention
Baseline 
characteristics 
mean (±SD)
Relevant 
outcomes
Meijer et al26
(DIPAK-1)
Randomised, open- 
label, ‘standard- of- 
care’ controlled trial
The 
Netherlands
30 309 (142)   eGFR of 30–60 mL/
min/1.73 m2
MRI Lanreotide- 
LAR, 120 mg 
intramuscularly 
every 28 days
eGFR
 Ź (I) 51.0±11.5
 Ź (C) 51.4±11.2
TKV
 Ź (I) 2046±1171
 Ź (C) 1874±1202
TKV, eGFR, 
blood pressure, 
blood glucose 
and adverse 
effects
Perico et al27
(ALADIN 2)
Randomised, double- 
blind, placebo- 
controlled trial
Italy 36 100 (57) eGFR between 15 and 
40 mL/min/1.73 m2
CT Octreotide- 
LAR, 40 mg 
intramuscularly 
every 28 days
eGFR
 Ź (I) 27.9±10.15
 Ź (C) 25.8±6.44
TKV
 Ź (I) 2,338±1362
 Ź (C) 2,591±1876
TKV, eGFR, 
progression to 
ESRF, adverse 
events, blood 
glucose and 
blood pressure
van Aerts et al29 Secondary analysis of 
DIPAK-1
The 
Netherlands
30 175 (74) eGFR of 30–60 mL/
min/1.73 m2
MRI Lanreotide- 
LAR, 120 mg 
intramuscularly 
every 28 days
TKV
 Ź (I) 1528±883
 Ź (C) 1376±347
TLV
(C), control; eGFR, estimated glomerular iltration rate; (I), intervention; LAR, long- acting release;TKV, total kidney volume; TLV, total liver volume.
Table 1 Continued
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Figure 2 Bias risk assessment summary. Green symbols 
represent low risk, yellow unclear risk and red high risk.
personnel. DIPAK-1 and the subsequent secondary anal-
ysis by van Aerts et al29 did not report final TKV and 
TLV (although they did report absolute and percentage 
changes and changes from baseline in TKV and TLV), 
resulting in a high risk of bias for selective reporting. 
Visual inspection of funnel plots did not reveal signif-
icant publication bias (online supplementary figure 
1A- C).
Primary outcomes
Effect of somatostatin analogues on EGFR
Five studies reported the effects of somatostatin analogues 
on eGFR in 480 patients. There were no significant differ-
ences in eGFR decline for ADPKD patients treated with 
somatostatin analogues compared with placebo controls 
(mean difference 0.27 mL/min/1.73 m2, 95% CI −2.03 
to 2.57, p value=0.82, I2=0%) (figure 3A). There was 
no apparent difference in efficacy between lanreotide 
(mean difference −0.60 L, 95% CI −3.65 to 2.45, p=0.9, 
I2=N/A) and octreotide treatment (mean difference 0.16 
L, 95% CI −3.32 to 3.65, p=0.93, I2=0%) on eGFR (online 
supplementary figure 2A).
Effect of somatostatin analogues on TKV and TLV
Across the 6 studies in 497 patients, somatostatin analogue 
treatment did not result in a significant reduction in 
TKV for ADPKD patients when compared with placebo 
controls (mean difference −0.19 L, 95% CI −0.50 to 0.12, 
p value=0.23, I2=52%) (figure 3B). The level of heteroge-
neity in the studies for this outcome was high (I2 >50%). 
Sensitivity analysis showed no significant change in the 
overall effect when any single study was excluded but did 
demonstrate that the ALADIN 2013 and Hogan et al23 
studies were associated with the highest level of hetero-
geneity. This was likely the result of variation in baseline 
TKV between control and treatment groups. Due to the 
limited number of studies available (less than 10) however, 
a meta- regression to account for baseline TKV could not be 
performed. Therefore, a further analysis assessing the differ-
ence between pretreatment and post- treatment means was 
conducted. This analysis demonstrated a mean difference 
of −124 mL (95% CI −190 to 58.7, p value=0.0002, I2=0%) 
in TKV for participants treated with somatostatin analogues 
compared with placebo- treated participants (online supple-
mentary figure 3). TLV was lower in somatostatin analogue- 
treated participants compared with controls across the 5 
studies which included 311 patients (mean difference −0.15 
L, 95% CI −0.26 to −0.03, p=0.01, I2=0%) (figure 3C). When 
studies are separated by choice of somatostatin analogue 
agent, lanreotide (mean difference −0.15 L, 95% CI −0.21 
to −0.1, p<0.00001, I2=0%) appeared to be of more benefit 
when compared with octreotide (mean difference −0.28 L, 
95% CI −0.91 to 0.35, p=0.38, I2=71%) for TKV outcomes 
(online supplementary figure 2B). Furthermore, lanreotide 
(mean difference −0.14 L, 95% CI −0.26 to −0.02, p=0.02, 
I2=0%) also demonstrated a significant reduction in TLV, a 
finding which was not observed in the octreotide subgroup 
(mean difference −0.17 L, 95% CI −0.46 to 0.12, p=0.25, 
I2=0%) (online supplementary figure 2C).
Secondary outcomes
Effect of somatostatin analogues on BP
Systolic and diastolic BP were reported in four studies. 
Compared with placebo, somatostatin treatment did not 
significantly alter systolic BP (mean difference 1.24 mm 
Hg, 95% CI −0.83 to 3.31, p value=0.24, I2=0%) (online 
supplementary figure 4A) or diastolic BP (mean differ-
ence 0.47 mm Hg, 95% CI −0.97 to 1.91, p value=0.52, 
I2=0%) (online supplementary figure 4B).
Adverse effects of somatostatin analogues
Across 5 studies and a total of 500 patients, somatostatin 
analogue treatment resulted in a significant increase in blood 
glucose (standardised mean difference 0.48, 95% CI 0.19 
to 0.77, p value=0.001, I2=49%) (figure 4A). Somatostatin 
analogues increased the risk of known side effects such as 
diarrhoea (RR 4.83, 95% CI 2.26 to 10.34, p value<0.001, 
I2=70.9%), abdominal pain (RR 2.86, 95% CI 1.50 to 5.45, 
p value=0.001, I2=63%), cholelithiasis and cholecystitis (RR 
4.8, 95% CI 1.22 to 18.81, p value=0.02, I2=0%) and alopecia 
(RR 5.88, 95% CI 1.3 to 26.61, p value=0.02, I2=0.0%) 
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Figure 3 Primary outcomes. Somatostatin treatment has no effect on eGFR or TKV but reduces TLV. Forest plots depicting 
the effects of somatostatin analogue versus controls on eGFR (A), TKV (B) and TLV (C). Horizontal lines represent the 95% CIs. 
The studies with mean difference were indicated by coloured square. The diamond represented pooled mean difference analysis 
with a 95% CI. eGFR,estimated glomerular iltration rate; TKV,total kidney volume; TLV, total liver volume.
(figure 4B–E). Furthermore, somatostatin analogue 
treatment was associated with an increased discontinu-
ation rate (RR 2.64, 95% CI 1.57 to 4.46, p value=0.0003, 
I2=35%) compared with control groups (figure 4F). Given 
the moderate to high degree of heterogeneity in multiple 
outcomes, a sensitivity analysis was performed. However, 
there was no change to the overall effect for these outcomes 
with the exclusion of any single study.
Effect of somatostatin analogues on progression to ESRF or need 
for Renal Replacement Therapy (RRT)
Progression to RRT was reported only in two studies: 
DIPAK-1 and ALADIN 2. Across the 405 patients analysed, 
6 patients treated with lanreotide and 10 from the placebo 
groups progressed to ESRF requiring RRT. Somatostatin 
treatment had no significant effect on the progression to 
ESRF (RR 0.64, 95% CI 0.16 to 2.49, p value=0.52) (online 
supplementary figure 4C). There was a moderate level of 
heterogeneity associated with these results (I2=39%).
Effect of somatostatin analogues on mortality and rate of 
hospital admissions
Mortality rates and rates of hospital admissions were not 
reported in any study.
DISCUSSION
To our knowledge, this is the first systematic review and 
meta- analysis of the clinical efficacy and safety of soma-
tostatin analogues in ADPKD and PLD. The results 
of this analysis demonstrate that while treatment with 
somatostatin analogues in ADPKD and PLD results in 
reduced TLV, there was no improvement in eGFR or the 
rate of progression to ESRF requiring RRT. Our results 
also found no improvement in TKV with somatostatin 
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Figure 4 Adverse effects of somatostatin treatment. Forest plots depicting the effect of somatostatin analogue treatment 
versus control on blood glucose (A), diarrhoea (B), abdominal pain (C), cholelithiasis and cholecystitis (D), alopecia (E) and 
discontinuation rates (F). Treatment with somatostatin resulted in increased risk of all assessed adverse effects. Horizontal lines 
represent the 95% CIs. The studies with risk ratio or standardised mean difference were indicated by coloured square. The 
diamond represented pooled risk ratio or standardised mean difference analysis with a 95% CI.
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analogue treatment. However, this was complicated by 
significant heterogeneity in these studies with differences 
in baseline TKV between control and treatment groups.
Somatostatin analogue treatment reduces TKV but does not 
improve EGFR
Although we were unable to use meta- regression, differ-
ence between means analysis suggests an improvement 
in TKV with somatostatin analogues. Our result is consis-
tent with individual studies reporting a small reduction 
in the increase of TKV. In contrast, neither individual 
studies nor this meta- analysis demonstrated an effect on 
eGFR. TKV has been accepted as a prognostic biomarker 
by the US Food and Drug Agency (FDA) and European 
Medicines Agency (EMA) although its use as a surrogate 
disease or efficacy biomarker in patients with preserved 
renal function is still debated.32 The divergence between 
effects on TKV and eGFR is similar to that observed in 
previous clinical trials where a positive effect on TKV was 
associated with a neutral or negative effect on eGFR.2 The 
reasons for this difference are not clear but indicate that 
a change in TKV does not always equate to a benefit on 
renal function. Potentially, somatostatin analogues could 
themselves reduce GFR through haemodynamic changes 
although the effects reported so far in healthy controls 
and diabetic patients have been acute.33–35 Alternatively, 
the effects of somatostatin treatment on TKV may be too 
modest to translate into renal function improvement in a 
short clinical trial and more prolonged treatment period 
may be needed to demonstrate a measurable benefit 
on eGFR decline. However, this is likely to be offset by 
the downregulation of somatostatin receptors with 
prolonged exposure to somatostatin analogues, leading 
to reduced efficacy with long- term treatment.36 It should 
be noted that not all somatostatin analogues are identical 
with in vivo evidence that pasireotide is more effective 
than octreotide at inhibiting cyst development due to 
the broader range of somatostatin receptor subtypes it 
binds to and its longer half- life.37 Pasireotide is currently 
being investigated in an RCT for PLD (NCT01670110) 
although not for ADPKD.
There was significant variation among the studies with 
regards to follow- up period with the shortest follow- up 
period being 3 months and the longest being 3 years. 
The landmark TEMPO trial demonstrated significant 
renoprotective effects after 3 years of treatment38 and 
therefore shorter treatment periods may fail to detect 
protective effects. Only the ALADIN and ALADIN 2 trials 
followed patients up for 3 years and therefore this meta- 
analysis may potentially miss important effects at long 
periods of treatment.
Progression to ESRF was only reported by DIPAK-1 and 
ALADIN 2 with 16 patients reaching this end point. The 
inclusion criteria of ALADIN 2 had a lower eGFR (15 and 
40 mL/min/1.73 m2) than other studies and thus many 
patients who progressed to ESRF in the meta- analysis 
were from this study. ALADIN 2 alone showed a signifi-
cant reduction in the progression to ESRF and all of those 
that progressed to ESRF had CKD4 (excluded from all 
other RCTs). This does raise the possibility of a poten-
tial role for somatostatin analogues in ADPKD patients 
with advanced CKD, although further investigation will 
be needed to confirm this observation.
Somatostatin analogues reduce TLV
In contrast to TKV, there was a clear effect of somatostatin 
analogues in this meta- analysis showing a significant 
reduction in TLV (figure 3C). The reasons behind this 
divergence are not clear. In ADPKD, women develop PLD 
more commonly than males and this is reflected in the 
larger number of female participants in trials where TLV 
was reported. Previous subgroup analysis of somatostatin 
analogues in PLD have demonstrated that women benefit 
more than men,17 and this may have exaggerated the 
benefits of treatment on TLV when compared with TKV 
where the gender difference has not been described.
Interestingly, several studies have commented that 
the benefits of somatostatin treatment may persist after 
treatment cessation. Indeed, Pisani et al reported that a 
residual volume reduction remained up to 5 years after 
treatment had ended and van Aerts et al reported TLV 
improvement throughout the 4- month washout period 
(long after the 28- day half- life of lanreotide).29 30 These 
results suggest that somatostatin analogue treatment could 
confer a long- term benefit on TLV in patients with PLD. 
One serious concern surrounding tolvaptan treatment in 
ADPKD and PLD is the association with hepatotoxicity. 
Both the major tolvaptan ADPKD trials (TEMPO38 and 
REPRISE39) demonstrated a significant risk of developing 
hepatotoxicity in 16 patients in the tolvaptan treatment 
group compared with 1 in the placebo group. The EMA 
have estimated a rare risk of severe hepatitis which may 
affect approximately 1 in 4000 ADPKD patients treated 
with tolvaptan.40
The association of hepatotoxicity with tolvaptan treat-
ment may limit its use in PLD, therefore somatostatin 
analogues may prove a suitable alternative. It is, however, 
important to note that somatostatin analogue treatments 
have been associated with gall stone formation and 
cholecystitis41 which was confirmed in our meta- analysis 
(figure 4D). This would have significance in patients 
with pre- existing liver disorders, including PLD. Careful 
safety analysis is likely to be required to assess the risks 
of somatostatin analogue and tolvaptan treatments in 
PLD. Screening for gallstones will likely be required 
before starting somatostatin analogue treatment in all 
PLD patients. In PLD, the treatment focus is not just 
on reducing TLV growth but also on improving symp-
toms and quality of life (QOL) measures.42 Patients 
with larger liver volumes report more frequent abdom-
inal symptoms43 and increased TLV has been shown to 
correlate with patient reported QOL.44 Indeed, soma-
tostatin analogues have been used off- label in severe PLD 
due to their effects on liver size and pooled analysis of 
two previous RCTs suggested that there was a benefit to 
patient reported QOL.45 While three trials did report 
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QOL, different questionnaires were used: DIPAK-1 used a 
validated ADPKD questionnaire while LOCKCYST24 and 
Hogan et al23 used the SF-36 questionnaire, thus limiting 
the possibility of including QOL as a secondary outcome. 
An RCT investigating the effects of pasireotide- LAR on 
PLD (NCT01670110) may provide further evidence in 
this area using a PLD- specific QOL questionnaire.46
Adverse effects of somatostatin analogue treatment
The adverse effects of somatostatin treatment reported 
were generally what would be expected from the 
known side effects of somatostatin analogues. The most 
commonly reported adverse events were abdominal 
pain and diarrhoea which have been widely reported as 
relatively mild and resolving spontaneously. There were 
also significant increases in the incidence of more clin-
ically important side effects such as cholelithiasis and 
cholecystitis, alopecia and increases in blood glucose. 
In the DIPAK-1 study, 7 of the 153 patients treated with 
lanreotide unexpectedly developed hepatic cyst infec-
tions.26 While all recovered from the acute episode with 
appropriate treatment, they required hospital admission 
and a prolonged course of antibiotic therapy of up to 90 
days. Caution will be required when prescribing soma-
tostatin analogues, particularly in patients with a history 
of hepatic cyst infections. Of interest, this complication 
was not observed in the ALADIN 2 study with the use of 
octreotide.25
CONCLUSIONS AND LIMITATIONS
Our meta- analysis was limited by the small number 
of studies and patients included. In all, 9 papers were 
included, 3 of which were secondary analyses of previous 
studies with a total of 592 patients. Blinding bias risk 
was high in four of the larger RCTs, the largest being 
open label without the use of placebo (DIPAK-1) and 
another (ALADIN) being single- blinded thus exposing 
them to a high risk of blinding bias. There was a distinct 
lack of large- scale clinical data available, with the largest 
trial (DIPAK-1) contributing 300 patients. The studies 
included were all from European countries or the USA, 
with most patients being Caucasian. This limits the appli-
cability of these results to other ethnic groups. There 
was also significant variation in choice of somatostatin 
analogue formulations between studies without a clear 
consensus emerging on the most appropriate agent. 
Our analysis suggests that lanreotide treatment may be 
of more benefit than octreotide with regards to TKV and 
TLV effects but the small number of studies will limit 
conclusions regarding optimal somatostatin agents at this 
point. The eGFR parameters for included patients varied 
significantly between trials, with some studies including 
participants only with CKD3/4 and others including those 
with normal renal function. We cannot exclude the possi-
bility that somatostatin analogues could be beneficial to 
participants with more advanced kidney failure which this 
meta- analysis did not detect. No study reported hospital 
admissions or mortality rates, likely due to the low overall 
mortality and rate of hospital admissions in the combined 
cohort.
It should be noted that several studies reported differ-
ences in baseline TKV between treatment and control 
groups which risked confounding results from a meta- 
analysis using final post- treatment means. This was 
apparent given the high heterogeneity across the studies 
when reporting TKV. While exploratory analysis suggests 
that the change of TKV from baseline was improved 
with somatostatin treatment, this method of analysis is 
susceptible to bias. A meta- regression would normally 
be performed to account for the baseline differences 
although this is not recommended in meta- analyses with 
fewer than 10 studies.20
Overall our results do not currently support a role for 
somatostatin analogues in slowing renal disease progres-
sion in ADPKD. There may be potential for a limited role 
in reducing liver cyst burden in patients with severe PLD 
and in patients with advanced CKD in limiting progres-
sion to ESRF, although confirmatory evidence from 
future trials is required.
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